Alpha Tau Medical Ltd. Price & Performance (DRTSW)

Alpha Tau Medical has received FDA approval to begin a clinical trial targeting recurrent glioblastoma, a highly aggressive brain cancer. The approval highlights ongoing regulatory momentum for Alpha Tau’s Alpha DaRT therapy, which is already under evaluation in multiple cancer types, including pancreatic and head and neck cancers. The company continues to expand its clinical pipeline.12

Recent filings reveal that institutional investors, including Renaissance Technologies and Northern Trust, have sharply increased their stakes in Alpha Tau Medical. Meanwhile, short interest in the company’s shares jumped by over 60% in March, reflecting heightened market activity and diverging investor sentiment regarding the company’s future prospects.34

Alpha Tau Medical’s stock dipped 1.12% to $2.64 on Thursday, even as technical indicators suggest a generally positive outlook. The stock has shown controlled volatility and recent buy signals, though analysts caution about low liquidity and the possibility of further short-term declines if support levels are breached.56